Skip to main content

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System BREATHE is scheduled to implant up to 229 patients at up to 25 U.S. centers, followed for up to five years, to evaluate the long-term safety and effectiveness of the Genio therapy in real-world clinical practice First implant performed by Rolando Molina, MD, South Florida ENT Associates, with Edward Mezerhane, MD, of PharmaDev Clinical Research Institute as Site Principal Investigator Mont-Saint-Guibert, Belgium – September 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the first patient has been implanted in BREATHE,...

Continue reading

Publication of H1 2026 Report

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)07 September 2026 – Theon International Plc (THEON) is pleased to announce the publication of its H1 2026 Report for the six months ended 30 June 2026 which is now available on the IR website. This follows the H1 2026 Trading Update published on 27 July 2026, with the key financials reiterated. The Company is holding a live webcast for analysts and investors tomorrow (08 September 2026) at 3:00 PM EEST (1:00 PM BST). The webcast details are accessible here. H1 2026 Overview As previously announced, H1 2026 performance was characterised by strong revenue growth (35.4%), industry-leading profitability (Adjusted EBIT margin 26.2%), a sustained book-to-bill ratio of c 1.0x, and significant expansion of THEON’s addressable market to nearly €8 billion due to expansion into high-growth...

Continue reading

VRANKEN-POMMERY MONOPOLE – AVAILABILITY OF THE 2026 HALF-YEAR FINANCIAL REPORT

Press ReleaseAvailability of the 2026 half-year Financial Report Reims, September 7th 2026 MAISON POMMERY & ASSOCIES has filed today its 2026 half-year Financial Report with the French Autorité des Marchés Financiers (AMF). It is available to the public under the conditions set out in the regulations in force and can be downloaded from the Group’s website in the Investor Relations / Press Releases and Regulated Information section at the following address: https://www.maisonpommery.com/en/type-presse/financial-reports/ Maison Pommery & Associés is a major player in the Champagne sector. The Group controls the entire value chain, from vine cultivation to wine production and marketing. The Group also has a presence in three other wine regions (Provence, Camargue, and Douro). It is strongly committed to promoting terroirs,...

Continue reading

Maison Pommery & Associés : First-half 2026 results

Financial Press ReleaseFirst-half 2026 results Commercial momentum driven by Champagne Pommery & GrenoConsolidated turnover of €96.2m i.e. +0.7% on a like-for-like basis1 (-12.0% as reported), including +7.1% for Champagne Pommery & Greno Net income of -€4.0m, down €2.5m, a direct consequence of the disposal of Heidsieck & Co Monopole, not fully offset over the half-year Reduction in net financial debt and Group financing secured until June 2027, with a possible extension to 2028Reims, September 7, 2026 The Board of Directors of Maison Pommery & Associés met on September 7, 2026 under the chairmanship of Mrs. Nathalie Vranken, and in the presence of the Statutory Auditors, notably to approve the Group’s consolidated financial statements for the first half of 2026. The limited review procedures on the half-year financial...

Continue reading

Interoil Exploration & Production ASA:

Minutes from Annual General Meeting Oslo, 7 September 2026: The Annual General Meeting of Interoil Exploration and Production ASA was held in Oslo on 7 September 2026. The minutes from the meeting are attached. This information is subject of the disclosure requirements of section 5-12 of the Norwegian Securities Trading Act. Please direct any further questions to: ir@interoil.no This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentIOX -AGM minutes 070926

Continue reading

Information regarding executed transactions within the framework of a share buyback programme (outside the liquidity agreement) from 31 August to 4 September 2026

(In accordance with article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programmes and stabilisation measures) As announced on Thursday 30 July 2026, Ayvens started on Friday 31 July 2026, an ordinary share buyback programme for a maximum amount of EUR 450 million for the purpose of shares cancellation. Ayvens received all necessary authorisations from supervisory authorities. The share buyback programme will be carried out in accordance with the provisions set out in the EU Regulation n°596/2014 of the European Parliament and of the Council of April 16th 2014, on market abuse, as modified, and its implementing provisions, and within the...

Continue reading

Detailed disclosure of trading in own shares from August 31 to September 4, 2026

Press Release 74Software: Disclosure of transactions in own shares Paris, September 7, 2026 – In accordance with the authorization given by the Combined General Meeting of May 19, 2026, for the implementation of a share buyback program, 74Software (LEI: 96950022O6SP7FQONJ77) declares below the purchases of its own shares (FR0011040500) from August 31 to September 4, 2026:TransactionDay Total Daily Volume(number of shares) Weighted Average Acquisition Price (€/share) Transaction Amount (€) Market Identification Code04/09/2026 1,400 39.00 54,600 XPARTOTAL 1,400 39.00 54,600 –Details of transactions, in accordance with Article 5(2)(c) of European Regulation No 596/2014 and its delegated regulation (EU) 2016/1056, are available on page 2 and following. Disclaimer This document is a translation into English of an original...

Continue reading

Correction: Form 8.3 – LondonMetric Property Plc & Schroder Real Estate Investment Trust Limited

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree A consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date...

Continue reading

Correction: A notice of the convening of the Extraordinary General Meeting of Shareholders of AB Amber Grid

The date of the Extraordinary General Meeting of Shareholders of AB Amber Grid has been updated to September 29, 2026 (from October 29, 2026). All other information remains unchanged. At the initiative of and subject to the Decision of 07 September 2026 of the Board of AB Amber Grid (company code 303090867), registered office address: Laisvės ave. 10, LT-04215 Vilnius, Lithuania (the “Company”), the Ordinary General Meeting of Shareholders (the “Meeting”) of the Company is convened. By its decision, the Board also approved the agenda of the Meeting and the draft of the decision.  The Meeting is convened at Laisvės ave. 10, LT-04215 Vilnius, Lithuania, Laisvės Energijos hall, on 29 September 2026 (on Tuesday), at 10:00 a.m. (Lithuanian time).  The beginning of the shareholders’ registration: on 29 September 2026, at 09:30 a.m. (Lithuanian...

Continue reading

Pharma Equity Group A/S – Challenge to Arbitral Award

  07 September 2026   Announcement no. 11   Pharma Equity Group A/S – Challenge to Arbitral Award   Pharma Equity Group A/S (“PEG”) has been notified that Interpatium – Promoção Imobiliária LDA has commenced proceedings before the District Court of Helsingør seeking to have the arbitral award dated 12 June 2026 set aside.   PEG disputes the grounds for the proceedings and will protect the Company’s interests throughout the legal process.   The commencement of the proceedings does not in itself suspend the enforceability of the arbitral award, and PEG will therefore continue its enforcement efforts pursuant to the award.   Under the arbitral award, Interpatium is required to pay PEG EUR 10.5 million plus interest and costs.   For further information, please contact:  Christian Vinding Thomsen, Chairman of the Board of Directors of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.